Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Thoracic 2Breast 2Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Wilms Tumor 6Osteosarcoma 6Neuroblastoma 6Leukemia, Myeloid, Acute 6Glioma 6Rhabdoid Tumor 5Neoplasm Metastasis 5Lymphoma, Non-Hodgkin 5Hepatoblastoma 5Sarcoma 4Rhabdomyosarcoma 4Neuroectodermal Tumors, Primitive, Peripheral 4Multiple Myeloma 4Medulloblastoma 4Histiocytosis, Langerhans-Cell 4Ependymoma 4Colorectal Neoplasms 4Carcinoma, Hepatocellular 4Breast Neoplasms 4Sarcoma, Ewing 3Prostatic Neoplasms 3Ovarian Neoplasms 3Myelodysplastic Syndromes 3Lymphoma 3Lung Neoplasms 3Endometrial Neoplasms 3Central Nervous System Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Mouth Neoplasms 2Melanoma 2

Interventions

Magnetic Resonance Spectroscopy 28enzalutamide 23Specimen Handling 20apalutamide 17Androgen Antagonists 14Radiosurgery 13Radiotherapy 12Prednisone 12Docetaxel 12Abiraterone Acetate 12abiraterone 10Biopsy 10Radiation 8niraparib 6luprolide acetate gel depot 6darolutamide 6Pluvicto 6Leuprolide 62-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 6relugolix 5gallium 68 PSMA-11 5cabazitaxel 5acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5Nivolumab 5Gonadotropin-Releasing Hormone 5bicalutamide 4Triptorelin Pamoate 4Surveys and Questionnaires 4Radiotherapy, Intensity-Modulated 4Glutamate Carboxypeptidase II 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Prostatic Neoplasms × X-Rays × 30 days × Clear all
NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT06982222 2026-05-13

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
24 enrolled
BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Prostatic Neoplasms

NCT07581184 2026-05-12

BActinium-1

Aktis Oncology, Inc.

Phase 1 Recruiting
138 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡